Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia

Blood

Volumn 107, Issue 6, 2006, Pages 2525-2530

  Corazza, Francis ^a   Hermans, Christophe ^b   D'Hondt, Stéphanie ^b   Ferster, Alina ^b   Kentos, Alain ^b   Benoît, Yves ^b   Sariban, Eric ^b  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GROWTH FACTOR; MARKER; PROTEIN; PROTEIN C FOS; PROTEIN C MPL; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; APLASTIC ANEMIA; APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER CHEMOTHERAPY; CELL CYCLE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA; UPREGULATION;

EID: 33644786946     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-06-2552     Document Type: Article

References (33)

1. Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene. 2002;21:3359-3367.
2. Chang M, Suen Y, Meng G, et al. Differential mechanisms in the regulation of endogenous levels of thrombopoietin and interleukin-11 during thrombocytopenia: insight into the regulation of platelet production. Blood. 1996;88:3354-3362.
3. Shimazaki C, Inaba T, Uchiyama H, et al. Serum thrombopoietin levels in patients undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1997;19:771-775.
4. Shinjo K, Takeshita A, Nakamura S, et al. Serum thrombopoietin levels in patients correlate inversely with platelet counts during chemotherapyinduced thrombocytopenia. Leukemia. 1998;12:295-300.
5. Emmons RV, Reid DM, Cohen RL, et al. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood. 1996;87:4068-4071.
6. Ichikawa N, Ishida F, Shimodaira S, Tahara T, Kato T, Kitano K. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thromb Haemost. 1996;76:156-160.
7. Kojima S, Matsuyama T, Kodera Y, Tahara T, Kato T. Measurement of endogenous plasma thrombopoietin in patients with acquired aplastic anaemia by a sensitive enzyme-linked immunosorbent assay. Br J Haematol. 1997;97:538-543.
8. Van Den Oudenrijn S, Bruin M, Folman CC, Bussel J, de Haas M, von dem Borne AE. Three parameters, plasma thrombopoietin levels, plasma glycocalicin levels and megakaryocyte culture, distinguish between different causes of congenital thrombocytopenia. Br J Haematol. 2002;117:390-398.
9. Hirai H, Shimazaki C, Yamagata N, et al. Effects of thrombopoietin (c-mpl ligand) on growth of blast cells from patients with transient abnormal myelopoiesis and acute myeloblastic leukemia. Eur J Haematol. 1997;59:38-46.
10. Piacibello W, Sanavio F, Brizzi MF, et al. Megakaryocyte growth and development factor (MGDF)-induced acute leukemia cell proliferation and clonal growth is associated with functional c-mpl. Leukemia. 1997;11:531-540.
11. Takeshita A, Shinjo K, Izumi M, et al Quantitative expression of thrombopoietin receptor on leukaemia cells from patients with acute myeloid leukaemia and acute lymphoblastic leukaemia. Br J Haematol. 1998;100:283-290.
12. Tokunaga Y, Miyamoto T, Okamura T, et al. Effect of thrombopoietin on proliferation of blasts from CD7-positive acute myelogenous leukaemia. Br J Haematol. 1998;102:1232-1240.
13. Tafuri A, Lemoli RM, Petrucci MT, et al. Thrombopoietin and interleukin 11 have different modulatory effects on cell cycle and programmed cell death in primary acute myeloid leukemia cells. Exp Hematol. 1999;27:1255-1263.
14. Iijima K, Sugita K, Inukai T, et al. Expression of thrombopoietin receptor and its functional role in human B-precursor leukemia cells with 11q23 translocation or Philadelphia chromosome. Leukemia. 2000;14:1598-1605.
15. Tamura H, Ogata K, Luo S, et al. Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. Br J Haematol. 1998;103:778-784.
16. Shinjo K, Takeshita A, Ohnishi K, Ohno R. Expression of granulocyte colony-stimulating factor receptor increases with differentiation in myeloid cells by a newly-devised quantitative flow-cytometric assay. Br J Haematol. 1995;91:783-794.
17. Methia N, Louache F, Vainchenker W, Wendling F. Oligodeoxynucleotides antisense to the protooncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood. 1993;82:1395-1401.
18. Kastan MB, Stone KD, Civin CI. Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. Blood. 1989;74:1517-1524.
19. Gibellini D, Re MC, Bassini A, et al. HIV-1 gp120 induces the activation of both c-fos and c-jun immediate-early genes in HEL megakaryocytic cells. Br J Haematol. 1999;104:81-86.
20. Hayez N, Harfi I, Lema-Kisoka R, Svoboda M, Corazza F, Sariban E. The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) modulate several biochemical pathways in human leukemic myeloid cells. J Neuroimmunol. 2004;149:167-181.
21. Dorsch M, Fan PD, Danial NN, Rothman PB, Goff SP. The thrombopoietin receptor can mediate proliferation without activation of the Jak-STAT pathway. J Exp Med. 1997;186:1947-1955.
22. Corazza F, Beguin Y, Bergmann P, et al. Anemia in children with cancer is associated with decreased erythropoietic activity and not with inadequate erythropoietin production. Blood. 1998;92:1793-1798.
23. Vigon I, Dreyfus F, Melle J, et al. Expression of the c-mpl proto-oncogene in human hematologic malignancies. Blood. 1993;82:877-883.
24. Bouscary D, Prudhomme C, Quesnel B, Melle J, Picard F, Dreyfus F. c-mpl expression in hematologic disorders. Leuk Lymphoma. 1995;17:19-26.
25. Matsumura I, Kanakura Y, Kato T, et al. Growth response of acute myeloblastic leukemia cells to recombinant human thrombopoietin. Blood. 1995;86:703-709.
26. Wetzler M, Baer MR, Bernstein SH, et al. Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. J Clin Oncol. 1997;15:2262-2268.
27. Mignotte V, Vigon I, Boucher de Crevecoeur E, Romeo PH, Lemarchandel V, Chretien S. Structure and transcription of the human c-mpl gene (MPL). Genomics. 1994;20:5-12.
28. Letestu R, Vitrat N, Masse A, et al. Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome. Blood. 2000;95:1633-1641.
29. Drachman JG, Griffin JD, Kaushansky K. The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem. 1995;270:4979-4982.
30. Kalina U, Hofmann WK, Koschmieder S, et al. Alteration of c-mpl-mediated signal transduction in CD34() cells from patients with myelodysplastic syndromes. Exp Hematol. 2000;28:1158-1163.
31. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
32. Kaushansky K. On the molecular origins of the chronic myeloproliferative disorders: it all makes sense. Blood. 2005;105:4187-4190.
33. Albitar M, Manshouri T, Kantarjian H, et al. Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk Res. 1999;23:63-69.